Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.30 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760982 | 1.00 | AKR1B1 (0.34) | AKR1B1PDE7AGPR17IDO1TDO2 | |
| SCHEMBL6603949 | 0.82 | KDM4E (0.34) | AKR1B1 | |
| SCHEMBL6603938 | 0.82 | KDM4E (0.34) | AKR1B1 | |
| SCHEMBL6611239 | 0.79 | MEN1 (0.32) | — | |
| SCHEMBL6611249 | 0.79 | MEN1 (0.32) | — | |
| SCHEMBL6606785 | 0.76 | VHL (0.40) | AKR1B1SHMT1SHMT2 | |
| SCHEMBL6761740 | 0.76 | VHL (0.40) | AKR1B1SHMT1SHMT2 | |
| Potassium Ion SCHEMBL6981616 | 0.74 | VHL (0.38) | AKR1B1SHMT1SHMT2 | |
| SCHEMBL6580397 | 0.70 | AKR1B1 (0.42) | AKR1B1PDE7AFABP4FABP5 | |
| SCHEMBL6605188 | 0.70 | AKR1B1 (0.42) | AKR1B1PDE7AFABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716834-B2 | ANTICOAGULANTS. | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| EP-1283837-B1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2003-11-27 | — | — | US | disclosed |
| EP-1283837-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087879-A1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | SERPINC1, F2, TFPI | AKR1B1 1031/4885PDE7A 1477/4885GPR17 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.